PIRS News and Press, Pieris Pharmaceuticals Inc. From 05/04/22

BOSTON, MA / ACCESSWIRE / May 4, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced...

Many people only want to own "safe," "mature," or "boring" stocks, and they ignore the opportunities in the risky side of the stock universe. What this does is create a pool of risky stocks with huge potential upside. And often these stocks can be bought relatively cheaply, which makes the ...

Although there is some risk, the potential upside of investing now in Pieris Pharmaceuticals (NASDAQ: PIRS) could be extraordinary. In this Motley Fool Live segment from "The Pharma & Biotech Show," recorded on March 23 , Fool.com contributors Taylor Carmichael and Keith...

Pieris Pharmaceuticals (NASDAQ: PIRS) is a micro-cap stock, but with big pharma now collaborating with the company, it may be time to consider an investment. In this Motley Fool Live segment from The Pharma & Biotech Show, recorded on March 23 , Fool.com contributor Tayl...

It's been an ugly year in the stock market so far, and both good and bad stocks have been hammered. Now's a great time to go shopping if you have the cash. Our roundtable has three biotech stocks that could be worth significantly more over the next three years than they are right now. H...

So far, 2022 has been an ugly year for a lot of stocks. But if you look out over the next five years, you can find some amazing opportunities. Our roundtable of three Motley Fool contributors has found three biotech stocks that might be 11-baggers in five years. Patrick Bafuma is bullis...

Pieris Pharmaceuticals, Inc. (PIRS) Q4 2021 Earnings Conference Call March 01, 2022, 08:00 ET Company Participants Stephen Yoder - CEO, President & Director Thomas Bures - SVP & CFO Shane Olwill - SVP & Chief Development Officer Conference Call Participants Jonathan Miller - Everc...

Pieris Pharmaceuticals press release (NASDAQ:PIRS): FY GAAP EPS of -$0.71 beats by $0.17. Revenue of $31.41M (+7.1% Y/Y) beats by $5.97M. For further details see: Pieris Pharmaceuticals GAAP EPS of -$0.71 beats by $0.17, revenue of $31.41M beats by $5.97M

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM EST Initiated efficacy part of phase 2a study of PRS-060/AZD1402; expected topline readout this year Dosed first patient in phase 2 gastric study of cinrebafusp alfa; HER2-low arm data expected this y...

Pieris Pharmaceuticals (NASDAQ:PIRS) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open. The consensus EPS Estimate is -$0.25 and the consensus Revenue Estimate is $2.45M For further details see: Pieris Pharmaceuticals Q4 2021 Earnings Preview